In the first quarter of this year, one case of dengue fever per day was registered in the cities of Greater ABC. In total, municipalities reported 86 cases in the first three months, compared with 108 in the same period last year, which is 20.4% less than the study by the Ministry of Health. Daily municipal data. São Caetano, with 34 cases, and Mauá, with 19 cases, are the cities with the highest records in 2022. Rio Grande da Serra, for its part, did not report the incident – see the table below for details.
Statistics of the region follow the development of the state. From January to early April, 44,000 cases of dengue fever were reported in São Paulo, up from 62,100 in the same period in 2021. According to the state health ministry, there were 145,000 infections and 71 deaths in 2021. No deaths have been reported in the municipalities of Grande ABC in the last two years.
The reduction in cases in the first months of the year was already expected at the time, as explained by Carlos Peçanha, Rentokil’s epidemiologist and technical director. He points out that the peak of dengue infections is usually in April-May, immediately after the most intense breeding season. Aedes Aegypti, which transmits dengue fever. “We have not yet reached the worst stage in the spread of dengue, zika or Chikungunya viruses. and extensive rainy seasons, says the doctor.
Marco Túlio Aguiar Mourão Ribeiro, vice-president of the SBMFC (Brazilian Society for Family and Community Medicine), confirms that the population must take care to prevent the spread of the virus, such as avoiding stagnant water in tires, pots and other containers. in addition to the use of repellents as part of family routines. “The main symptoms of infection are muscle pain, severe headache, fever and eye pain. In more severe cases, the disease can cause blemishes in the body, bleeding, nausea, and diarrhea, ”says the vice president, who recommends immediate hospitalization if any of these symptoms are observed.
The increase in cases on the national stage is already a reality. The number of dengue fever records rose 85 percent this year compared to the same period last year. According to the Ministry of Health, 323,900 probable cases were reported by the first half of April. The state of São Paulo is the pioneer with the highest number of confirmed deaths, with a total of 85 to date. [07.INTERT_CX]
In order to combat the virus in the area, all the municipalities stated that they are constantly taking preventive measures. Measures taken include awareness-raising campaigns to raise public awareness and inspections of buildings to prevent them from spreading.
In São Caetano, for example, Paço follows the guidelines of the National Mosquito Control Plan. Aedes Aegypti, from the Ministry of Health. As an innovative measure, Santo André passed a law in March this year, Law 10,476, which allows the use of drones to control dengue fever and other mosquito-borne diseases.
The vaccine against the disease is available online
Since 2015, a private health network has already made an immunizing agent available for dengue fever, an infectious disease spread by Aedes Aegypt that can also cause other diseases such as zikavirus and chikungunya.
The dose value exceeds R $ 300 and is not yet available on SUS (Unified Health System). It is recommended that three doses be given every six months only to patients aged 9 to 45 years who are already infected.
According to Alessandra Vivian Dorna Portela, a nurse and scientific director at Amo Vacinas Clinic, the immunizer is for people living in endemic areas with a high incidence of the disease. Patients who have already had one of the dengue serogroups 1, 2, 3, or 4 at the time of vaccination will prevent re-infection with dengue disease.
For more than 10 years, the Butantan Institute has been working with Niaid (the U.S. National Institute of Allergy and Infectious Diseases) to develop a vaccine against dengue fever. The immunizer is made by four attenuated viruses that produce antibodies without causing disease and with few side effects.
Since 2016, the study has been in its third phase, with 17,000 volunteers participating. The immunizer is currently in the follow-up phase – volunteers will be evaluated for five years. The study is expected to be completed by 2024.